Pharma Surge
Pharma Surge
Intelligence Layer
🌍·16h agodiscovery

Merck’s IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

Publisher

E
Endpoints News

Global

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Endpoints News
Region
Global
Scope
discovery
Published
June 22, 2026
Language
EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: Endpoints News

Scope: discovery

Open original article
Merck’s IBD drug from $10.8B Prometheus deal claims its first Phase 3 win | Pharma Surge